Over 85% of new CNS drug trials fail to achieve the desired endpoints. Some fail because efficacy cannot be established. Others fail because of operational issues, including low enrollment and poor data management. Incorporating leading scientific concepts at the start of the trial can create a cascade of benefits throughout.

With proprietary technology, an unrivaled database, and a cadre of the world’s leading experts in the study of neuroscience and neurodegenerative disease, WCG MedAvante-ProPhase helps biopharma sponsors to mitigate the operational variability that interferes with good, clean science – a requisite to proper research.